A 21-gene assay identified patients with early-stage, estrogen receptor-positive breast cancer who had a low risk of recurrence and could safely forgo adjuvant chemotherapy, reducing overtreatment and costs, researchers reported in the Journal of the National Comprehensive Cancer Network.
Genetic testing may cut costs, overtreatment in early breast cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.